Lilly posts Lyumjev safety results in India; registers new Alzheimer's Phase 1 study
Three registry updates this week span a completed diabetes safety trial with posted results, a new Phase 1 Alzheimer's study, and a completed alopecia trial sponsored with a collaborator.
Three clinical trial registry records tied to Eli Lilly and Company were updated this week, ranging from newly posted results to a not-yet-recruiting study.
- A Phase 4 study of insulin lispro-aabc (Lyumjev) in adult patients with Type 2 diabetes mellitus in India, sponsored by Eli Lilly with Cipla Ltd. as collaborator, is now marked completed with results posted. The study assessed the safety of insulin lispro-aabc in adult participants with Type 2 diabetes mellitus in India.1 Enrollment was 153 participants (actual).1
- A new Phase 1 study of LY4560736 in healthy participants and participants with Alzheimer's Disease was first posted and is not yet recruiting. The study aims to evaluate how safe LY4560736 is and to measure how much and how quickly the drug enters the bloodstream.2 Estimated enrollment is 111 participants2, with a start estimated for 2026-10.
- A Phase 2 study of baricitinib (Olumiant) in adult patients of African descent with biopsy-proven central centrifugal cicatricial alopecia is completed, sponsored by Raven Clinical Research with Eli Lilly and Company as collaborator. The study evaluated the safety and efficacy of baricitinib 4 mg daily in adults of African descent with biopsy-proven central centrifugal cicatricial alopecia, a scarring alopecia for which no FDA-approved treatment exists.3 Twenty-seven participants received at least one dose and 17 completed the Day 365 visit.3
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.